Open language selectionOpen language selection English Menu Search

Sarcoidosis and COVID-19 Impact Survey

The survey aims to answer questions including:

Preliminary Results 

To date, over 1600 sarcoidosis patients have responded to the survey. Of these, only 31 patients – less than 2%– reported having COVID-19. Most were able to be treated at home and none required mechanical ventilation. Researchers were unable to identify an increased risk associated with race, use of prednisone, or treatment with infliximab (Remicade). Also, the use of hydroxychloroquine (plaquenil) was neither protective nor a risk factor for infection. The study is ongoing and will include a follow up questionnaire in July.

Take part in the survey